Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK; Centre for Sexual Health and HIV Research, Department of Infection and Population Health, University College London, London, UK.
Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK.
Lancet Public Health. 2017 Jan;2(1):e35-e46. doi: 10.1016/S2468-2667(16)30020-2. Epub 2016 Dec 15.
Deaths in HIV-positive people have decreased since the introduction of highly active antiretroviral therapy (HAART) in 1996. Fewer AIDS-related deaths and an ageing cohort have resulted in an increase in the proportion of HIV patients dying from non-AIDS-related disorders. Here we describe mortality and causes of death in people diagnosed with HIV in the HAART era compared with the general population.
In this observational analysis, we linked cohort data collected by Public Health England (PHE) for individuals aged 15 years and older, diagnosed with HIV in England and Wales from 1997 to 2012, to the Office for National Statistics (ONS) national mortality register. Cohort inclusion began at diagnosis with follow-up clinical information collected every year from all 220 National Health Service (NHS) HIV outpatient clinics nationwide. To classify causes of death we used a modified Coding Causes of Death in HIV (CoDe) protocol, which uses death certificate data and clinical markers. We applied Kaplan-Meier analysis for survival curves and mortality rate estimation and Cox regression to establish independent predictors of all-cause mortality, adjusting for sex, infection route, age at diagnosis, region of birth, year of diagnosis, late diagnosis, and history of HAART. We used standardised mortality ratios (SMRs) to make comparisons with the general population.
Between 1997 and 2012, 88 994 people were diagnosed with HIV, contributing 448 839 person-years of follow up. By the end of 2012, 5302 (6%) patients had died (all-cause mortality 118 per 10 000 person-years, 95% CI 115-121). In multivariable analysis, late diagnosis was a strong predictor of death (hazard ratio [HR] 3·50, 95% CI 3·13-3·92). People diagnosed more recently had a lower risk of death (2003-07: HR 0·66, 95% CI 0·62-0·70; 2008-12: HR 0·65, 95% CI 0·60-0·71). Cause of death was determinable for 4808 (91%) of 5302 patients; most deaths (2791 [58%] of 4808) were attributable to AIDS-defining illnesses. Cohort mortality was significantly higher than the general population for all causes (SMR 5·7, 95% CI 5·5-5·8), particularly non-AIDS infections (10·8, 9·8-12·0) and liver disease (3·7, 3·3-4·2). All-cause mortality was highest in the year after diagnosis (SMR 24·3, 95% CI 23·4-25·2).
Despite the availability of free treatment and care in the UK, AIDS continues to account for the majority of deaths in HIV-positive people, and mortality remains higher in HIV-positive people than in the general population. These findings highlight the importance of prompt diagnosis, care engagement, and optimum management of comorbidities in reducing mortality in people with HIV.
Public Health England.
自 1996 年引入高效抗逆转录病毒疗法(HAART)以来,艾滋病毒阳性人群的死亡人数有所下降。艾滋病相关死亡人数减少和年龄较大的人群导致因非艾滋病相关疾病而死亡的艾滋病毒患者比例增加。在这里,我们描述了在 HAART 时代与普通人群相比,艾滋病毒感染者的死亡率和死亡原因。
在这项观察性分析中,我们将英格兰和威尔士 1997 年至 2012 年间诊断出的艾滋病毒感染者的公共卫生英格兰(PHE)收集的队列数据与国家统计局(ONS)国家死亡率登记处进行了关联。队列纳入始于诊断时,每年从全国 220 家国家卫生服务(NHS)艾滋病毒门诊诊所收集临床信息。为了分类死因,我们使用了改良的 HIV 死因编码(CoDe)方案,该方案使用死亡证明数据和临床标志物。我们应用 Kaplan-Meier 分析生存曲线和死亡率估计,并应用 Cox 回归确定全因死亡率的独立预测因素,调整性别、感染途径、诊断时年龄、出生地、诊断年份、晚期诊断和 HAART 治疗史。我们使用标准化死亡率比(SMR)与普通人群进行比较。
在 1997 年至 2012 年间,有 88994 人被诊断出患有 HIV,随访时间为 448839 人年。截至 2012 年底,5302 人(6%)死亡(全因死亡率为每 10000 人年 118 人,95%CI 115-121)。在多变量分析中,晚期诊断是死亡的一个强有力的预测因素(危险比[HR]3.50,95%CI 3.13-3.92)。最近诊断的患者死亡风险较低(2003-07:HR 0.66,95%CI 0.62-0.70;2008-12:HR 0.65,95%CI 0.60-0.71)。4808 名(91%)5302 名患者的死因可确定;大多数死亡(4808 名中的 2791 名[58%])归因于艾滋病定义性疾病。所有原因的队列死亡率均显著高于普通人群(SMR 5.7,95%CI 5.5-5.8),尤其是非艾滋病感染(10.8,9.8-12.0)和肝脏疾病(3.7,3.3-4.2)。诊断后第一年的全因死亡率最高(SMR 24.3,95%CI 23.4-25.2)。
尽管英国提供了免费的治疗和护理,但艾滋病仍然是艾滋病毒阳性人群死亡的主要原因,艾滋病毒阳性人群的死亡率仍然高于普通人群。这些发现强调了及时诊断、护理参与以及最佳管理合并症对于降低艾滋病毒感染者的死亡率的重要性。
英国公共卫生署。